
FDA rejects PTC Therapeutics’ drug for Friedreich’s ataxia
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) stating its decision not to recommend PTC Therapeutics’ vatiquinone for Friedreich’s ataxia (FA). The FDA stated in the CRL that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional… Read More



